**Supplementary material**

Table 4

*Comparison of baseline demographic, clinical and treatment characteristics for group completers only*

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable**  | **CR (*n* = 22)** | **CG (*n* = 21)** | **Test statistic(*p*)** |
| Diagnosis, *n* (%) |  |  |  |
|  Schizophrenia | 17 (77%) | 14 (67%) | *χ2*= 0.60 (.44) |
|  Schizoaffective disorder | 5 (23%) | 7 (33%) |  |
| Age, *M* years (*SD*) | 41.55 (9.73) | 40.62 (8.99) | *t* = 0.32 (.75) |
| Time since diagnosis, *M* years (*SD*)  | 14.14 (8.28) | 12.85 (7.36) 1 | *t* = 0.53 (.60) |
| Gender, *n* (%) |  |  |  |
|  Male | 14 (64%) | 15 (71%) | *χ2*= 0.30 (.59) |
|  Female | 8 (36%) | 6 (29%) |  |
| Caucasian, *n* (%) | 19 (86%) | 18 (86%) | *χ2*= 0.00 (.95) |
| English first language, *n* (%) | 18 (82%) | 20 (95%) | *χ2*= 1.88 (.17) |
| Single / never married, *n* (%) | 19 (86%) | 19 (91%) | *χ2*= 0.18 (.67) |
| WTAR, *M* scaled score (*SD*) | 98.45 (18.96) | 98.15 (10.99) 1 | *t* = 0.06 (.95) |
| Total education, *M* years (*SD*) | 14.09 (3.28) | 12.71 (2.49) | *t* = 1.02 (.13) |
| MCCB global, *M* (*SD*) | 30.82 (11.65) | 32.52 (10.71) | *t* = -0.50 (.62) |
| ILSS-SR total, *M* (*SD*) | 0.71 (0.15) | 0.72 (0.13) | *t* = -0.29 (.77) |
| RSES global, *M* (*SD*) | 98.14 (22.67) | 110.95 (20.39) | *t* = -1.95 (.06) |
| EUROHIS-QOL total, *M (SD)* | 26.95 (4.59) | 26.57 (5.27) | *t* = 0.26 (.80) |
| PANSS, *M* (*SD*) |  |  |  |
|  Positive | 15.68 (5.01) | 14.52 (5.13) | *t* = 0.75 (.46) |
|  Negative | 16.18 (6.95) | 14.57 (3.99) | *t* = 0.94 (.36) |
|  General | 29.95 (8.84) | 31.19 (7.87) | *t* = -0.48 (.63) |
|  Total | 61.82 (16.51) | 60.23 (13.50) | *t* = 0.33 (.74) |
| Antipsychotic medication, *n* (%) |  |  |  |
|  Atypical only | 20 (91%) | 16 (76%) | *χ2*= 1.71 (.19) |
|  Typical only | 1 (4.5%) | 2 (9.5%) | - |
|  Combination | 1 (4.5%) | 2 (9.5%) | - |
|  None | 0 (0%) | 1 (5%) | - |
| CPZE, *M* mg/day *(SD)* | 731.59 (476.35) | 698.25 (477.85) | *t* = 0.23 (.82) |
| Antidepressant medication, *n* (%)  | 4 (18%) | 8 (38%) | *t* = 2.12 (.15) |
| Mood stabilizers, *n* (%) | 6 (27%) | 5 (24%) | *χ2*= 0.07 (.80) |
| Concurrent psychopathology, *n* (%) |  |  |  |
|  Depressive disorder | 7 (32%) | 3 (14%) | *χ2*= 1.85 (.17) |
|  Anxiety disorder | 4 (18%) | 4 (19%) | *χ2*= 0.01 (.94) |
|  Alcohol and/or other drug abuse | 1 (5%) 2 | 3 (14%) | - |

1 *N* = 20; 2 N = 21; CR = Cognitive remediation; CG = Computer games; CPZE = Chloropromazine ewuivalence (see Woods, 2003); EUROHIS-QOL = European Health Interview Survey – Quality of Life; ILSS-SR = Independent Living Skills Survey – Self-Report; M = Mean; MCCB = Matrics Consenus Cognitive Battery; PANSS = Positive and Negative Syptom Scale; RSES = Revised Self-Efficacy Scale; SD = Standard deviation; WTAR = Weschler Test of Adult Reading.